Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 20/20 | 0.80 |
| ▸ | FNTB | P49356 | 20/20 | 0.80 |
| ▸ | HRAS | P01112 | 1/20 | 0.80 |
| ▸ | KRAS | P01116 | 1/20 | 0.80 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10039032 | 0.91 | FNTA (0.80) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL29171478 | 0.90 | FNTA (0.79) | FNTAFNTBHRASKRASPGGT1B | |
| Bms-214662 SCHEMBL16499911 | 0.89 | FNTA (1.00) | FNTAFNTBHRASKRASPGGT1B | |
| Bms-214662 SCHEMBL94663 | 0.89 | FNTA (1.00) | FNTAFNTBHRASKRASPGGT1B | |
| Bms-214662 SCHEMBL30498791 | 0.88 | FNTA (0.99) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL22050803 | 0.81 | FNTA (0.86) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL12193488 | 0.78 | FNTA (0.65) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL13300962 | 0.77 | FNTA (0.80) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL15977117 | 0.77 | FNTA (0.77) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL13186538 | 0.75 | FNTA (0.58) | FNTAFNTBHRASKRASPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS GROUP, INC. (US) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | KRAS, NRAS, TP53 | FNTA 1114/4885FNTB 1259/4885HRAS 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.